HSD11B2

hydroxysteroid 11-beta dehydrogenase 2, the group of Short chain dehydrogenase/reductase superfamily

Basic information

Region (hg38): 16:67430652-67437553

Links

ENSG00000176387NCBI:3291OMIM:614232HGNC:5209Uniprot:P80365AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • apparent mineralocorticoid excess (Strong), mode of inheritance: AR
  • apparent mineralocorticoid excess (Supportive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Cortisol 11-beta-ketoreductase deficiencyARRenalThere is a broad range of severity, including potentially lethal early chidlhood disease, and medical treatment (eg, with spironolactone) can be beneficialEndocrine; Renal870517; 1740492; 3460996; 3164727; 8370690; 7670488; 9683587; 9707624; 10536001; 10523339; 17314322; 19909806

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the HSD11B2 gene.

  • not provided (3 variants)
  • Apparent mineralocorticoid excess (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the HSD11B2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
21
clinvar
4
clinvar
25
missense
4
clinvar
39
clinvar
3
clinvar
2
clinvar
48
nonsense
0
start loss
0
frameshift
4
clinvar
4
inframe indel
1
clinvar
1
clinvar
2
splice donor/acceptor (+/-2bp)
0
splice region
1
1
2
non coding
5
clinvar
3
clinvar
8
Total 4 5 40 29 9

Highest pathogenic variant AF is 0.00000669

Variants in HSD11B2

This is a list of pathogenic ClinVar variants found in the HSD11B2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
16-67430908-G-A Likely benign (Nov 26, 2019)1208628
16-67430991-G-A Benign (Nov 24, 2020)1231382
16-67431272-G-A Likely benign (Mar 31, 2022)1978718
16-67431290-C-G Benign (May 01, 2023)2967700
16-67431290-C-T Likely benign (Jan 04, 2024)2980662
16-67431321-C-A Inborn genetic diseases Uncertain significance (Sep 07, 2022)2311051
16-67431324-TCA-T Apparent mineralocorticoid excess Pathogenic (Apr 01, 2007)31132
16-67431328-ACCTGCGTCTGGGCCGCCCGCTGCTGGCGGCGCTGGCGCTGCTGGCCGCGCTCGACTGGCTGTGCCAGCGCCTGCTGCCCCCGCCGGCCGCACTCG-A Pathogenic (Oct 03, 2022)2033856
16-67431347-G-A Likely benign (Jan 01, 2023)2498668
16-67431372-G-A Benign (Sep 05, 2022)1989648
16-67431407-CCCGCCGGCCGCACTCGCCGTGCTGGCCG-C Pathogenic (Aug 04, 2023)2876313
16-67431412-C-T Inborn genetic diseases Likely benign (Jan 30, 2024)3107081
16-67431420-C-T Inborn genetic diseases Uncertain significance (Jan 10, 2023)2474993
16-67431425-C-A not specified Benign/Likely benign (Nov 02, 2023)1256385
16-67431431-G-A Likely benign (Aug 04, 2023)2870444
16-67431440-C-CGCA Uncertain significance (Dec 21, 2023)2008819
16-67431458-C-T Likely benign (Nov 16, 2023)3002002
16-67431468-CGC-GG Apparent mineralocorticoid excess Uncertain significance (Dec 30, 2017)623310
16-67431484-C-G Inborn genetic diseases Uncertain significance (Sep 25, 2023)3107082
16-67431484-C-T Inborn genetic diseases Uncertain significance (Feb 14, 2023)2483713
16-67435628-G-A not specified • Apparent mineralocorticoid excess • HSD11B2-related disorder Conflicting classifications of pathogenicity (Aug 26, 2024)447525
16-67435634-A-C Apparent mineralocorticoid excess Uncertain significance (Apr 20, 2017)438714
16-67435673-C-G Inborn genetic diseases Uncertain significance (Mar 31, 2024)3284843
16-67435680-C-T Likely benign (Jul 25, 2023)2885399
16-67435698-C-T Likely benign (Jul 29, 2022)2192958

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
HSD11B2protein_codingprotein_codingENST00000326152 56902
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.1180.859125723091257320.0000358
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.021622030.7980.00001462520
Missense in Polyphen4372.5650.592581024
Synonymous-0.06398988.21.010.00000620929
Loss of Function1.9539.470.3174.14e-7141

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001190.000119
Ashkenazi Jewish0.00009990.0000992
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.00004450.0000440
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids.;
Pathway
Steroid hormone biosynthesis - Homo sapiens (human);Aldosterone-regulated sodium reabsorption - Homo sapiens (human);Steroidogenesis;Apparent mineralocorticoid excess syndrome;3-Beta-Hydroxysteroid Dehydrogenase Deficiency;21-hydroxylase deficiency (CYP21);Corticosterone methyl oxidase I deficiency (CMO I);Corticosterone methyl oxidase II deficiency - CMO II;Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase Deficiency;Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase Deficiency;Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;17-alpha-hydroxylase deficiency (CYP17);11-beta-hydroxylase deficiency (CYP11B1);Glucocorticoid and Mineralcorticoid Metabolism;Prostaglandin Synthesis and Regulation;Metabolism of lipids;Androgen and estrogen biosynthesis and metabolism;Metabolism;Metabolism of steroid hormones;Metabolism of steroids;C21-steroid hormone biosynthesis and metabolism;Glucocorticoid biosynthesis;Steroid hormones (Consensus)

Recessive Scores

pRec
0.644

Intolerance Scores

loftool
0.130
rvis_EVS
-0.47
rvis_percentile_EVS
23.25

Haploinsufficiency Scores

pHI
0.726
hipred
Y
hipred_score
0.713
ghis
0.467

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.993

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Hsd11b2
Phenotype
muscle phenotype; cellular phenotype; homeostasis/metabolism phenotype; neoplasm; digestive/alimentary phenotype; renal/urinary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan);

Gene ontology

Biological process
response to hypoxia;regulation of blood volume by renal aldosterone;glucocorticoid biosynthetic process;female pregnancy;response to food;response to insulin;response to drug;response to glucocorticoid;oxidation-reduction process
Cellular component
endoplasmic reticulum membrane
Molecular function
11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity;steroid binding;NAD binding